NEW YORK – As clinicians and scientists have worked to understand and control the spread and scope of the SARS-CoV-2 pandemic, molecular testing and serology have emerged as important tools for diagnosing and studying the disease.

Protein-based antigen testing has received relatively less attention, but several companies now have such tests in the works with plans to release them for clinical use within the next several months. Given their rapid turnaround time, ease of use, and amenability to large scale production, these tests could prove valuable for addressing the outbreak.